Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the ...

Germantown: Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

US FDA approves Precigen’s Papzimeos for the treatment of adults with recurrent respiratory papillomatosis: Germantown, Maryland Monday, August 18, 2025, 17:00 Hrs [IST] Precige ...

Precigen’s immunotherapy will likely reduce the need for repeat surgeries in recurrent respiratory papillomatosis (RRP) patients.

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...

Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ...

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

An update from Precigen ( ($PGEN) ) is now available. On August 18, 2025, Precigen, Inc. announced that its product PAPZIMEOS received FDA ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...